Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll
The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc. alum Katherine High as president, therapeutics. As president and head of R&D at Spark, High led the development and regulatory approval of Luxturna voretigene neparvovec-rzyl, the first in vivo gene therapy to be approved by FDA. Most recently, High was a visiting professor at Rockefeller University. She was on the faculty of the University of Pennsylvania and the medical staff at The Children’s Hospital of Philadelphia, where she was also an investigator at the Howard Hughes Medical Institute. Roche (SIX:ROG; OTCQX:RHHBY) acquired Spark for $4.8 billion.
Karl Rotthier joined Sanofi (Euronext:SAN; NASDAQ:SNY) as CEO of EuroAPI. Rotthier was most recently CEO of Centrient Pharmaceuticals Netherlands B.V. Sanofi said the new company may spin out with an IPO on Euronext Paris in 2022, at which time the pharma says EuroAPI will be the largest API company in the EU, with about €1 billion ($1.2 billion) in expected sales...